Investor Presentaiton

Comprehensive mRNA flu vaccine program SP0273 mRNA Flu QIV Days 29 I sanofi n=65 & 65 Phase 1/2 study Flu QIV (modified mRNA) Safety and immunogenicity with 3 different LNPs mRNA Flu QIV Dose 1 MRNA Flu QIV Dose 2 n=65 & 65 Adults Adults MRNA Flu QIV Dose 3 n=65 & 65 & 18-64 yo ≥65 yo Fluzone Standard Dose n=60 & 60 Flublok n=60 & 60 Fluzone High-Dose n = 0 & 60 mRNA neuraminidase (NA) Days 29 mRNA NA Dose 1 n=30 & 30 Adults 18-64 yo Adults mRNA NA Dose 2 n=30 & 30 & ≥65 yo mRNA NA Dose 3 n=30 & 30 Fluzone High-Dose n=30 & 30 47 Vaccines Investor Event Neuraminidase (unmodified mRNA and LNP#1) - Pilot study to test neuraminidase immunogenicity

View entire presentation